Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report released on Monday,Benzinga reports. The brokerage currently has a $65.00 price target on the stock.

A number of other equities research analysts have also commented on GPCR. JMP Securities restated a “market outperform” rating and set a $89.00 price objective on shares of Structure Therapeutics in a report on Monday. Citigroup assumed coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective on the stock. HC Wainwright dropped their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Monday, May 12th. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and an average target price of $76.17.

Structure Therapeutics Stock Down 2.6%

Shares of NASDAQ:GPCR opened at $21.79 on Monday. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $47.48. The company’s fifty day simple moving average is $23.46 and its 200 day simple moving average is $24.04. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -25.05 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Research analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics in the 4th quarter valued at $34,000. National Bank of Canada FI increased its stake in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after buying an additional 2,766 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after buying an additional 455 shares during the last quarter. Finally, Assetmark Inc. grew its position in shares of Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after acquiring an additional 953 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.